Stockreport

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases , and Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clini [Read more]